CVE-2022-23503

TYPO3 vulnerable to Arbitrary Code Execution via Form Framework

Description

TYPO3 is an open source PHP based web content management system. Versions prior to 8.7.49, 9.5.38, 10.4.33, 11.5.20, and 12.1.1 are vulnerable to Code Injection. Due to the lack of separating user-submitted data from the internal configuration in the Form Designer backend module, it is possible to inject code instructions to be processed and executed via TypoScript as PHP code. The existence of individual TypoScript instructions for a particular form item and a valid backend user account with access to the form module are needed to exploit this vulnerability. This issue is patched in versions 8.7.49 ELTS, 9.5.38 ELTS, 10.4.33, 11.5.20, 12.1.1.

Category

7.5
CVSS
Severity: High
CVSS 3.1 •
EPSS 0.12%
Third-Party Advisory github.com
Affected: TYPO3 typo3
Published at:
Updated at:

References

Frequently Asked Questions

What is the severity of CVE-2022-23503?
CVE-2022-23503 has been scored as a high severity vulnerability.
How to fix CVE-2022-23503?
To fix CVE-2022-23503, make sure you are using an up-to-date version of the affected component(s) by checking the vendor release notes. As for now, there are no other specific guidelines available.
Is CVE-2022-23503 being actively exploited in the wild?
As for now, there are no information to confirm that CVE-2022-23503 is being actively exploited. According to its EPSS score, there is a ~0% probability that this vulnerability will be exploited by malicious actors in the next 30 days.
What software or system is affected by CVE-2022-23503?
CVE-2022-23503 affects TYPO3 typo3.
This platform uses data from the NIST NVD, MITRE CVE, MITRE CWE, First.org and CISA KEV but is not endorsed or certified by these entities. CVE is a registred trademark of the MITRE Corporation and the authoritative source of CVE content is MITRE's CVE web site. CWE is a registred trademark of the MITRE Corporation and the authoritative source of CWE content is MITRE's CWE web site.
© 2025 Under My Watch. All Rights Reserved.